AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20220045
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (oral casopitant [150 mg day 1, 50 mg days 2 and 3] and warfarin [days 1-10])
Trial: 20220045
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (oral casopitant 60 mg and warfarin [days 1-14])
Trial: 18069011
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) at energy density of 0.55 mJ/mm(2) (1000 impulses)
Trial: 18069011
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment with a dummy electrode
Trial: 9539614
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch (200/0.5) solution
Trial: 7840167
Drug: DHEA (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (500 mg)
Trial: 96459
Drug: Biperiden treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden treatment
Trial: 7065831
Drug: Standard three-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard three-week treatment
Trial: 31433782
Drug: Myrtus communis
RxNorm normalized name: MYRTUS COMMUNIS TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrtus communis herbal ointment
Trial: 31433782
Drug: Anti-hemorrhoid ointment
RxNorm normalized name: benzocaine Topical Ointment [Americaine Hemorrhoidal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hemorrhoid ointment
Trial: 30237155
Drug: Immediate compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate compression therapy (multilayer bandaging or compression hosiery, pressure 35 mm Hg)
Trial: 27554689
Drug: No compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No compression therapy
Trial: 19917869
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (anthracycline/taxane-based)
Trial: 2198635
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg (single dose) + Hydrochlorothiazide 50 mg
Trial: 2198635
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of Captopril 50 mg + Hydrochlorothiazide 50 mg
Trial: 2198635
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of Captopril 50 mg + Hydrochlorothiazide 50 mg
Trial: 31155415
Drug: delNS1‐H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delNS1‐H5N1 vaccine at 6.8 log10 TCID50/subject
Trial: 31155415
Drug: delNS1‐H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delNS1‐H5N1 vaccine at 7.5 log10 TCID50/subject
Trial: 31155415
Drug: delNS1‐H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delNS1‐H5N1 vaccine after 2nd immunization
Trial: 26646074
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (according to Touch Therapy) for four days from the first day postnatal
Trial: 19228234
Drug: Gold standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold standard treatment (acetaminophen/paracetamol or non-steroidal anti-inflammatory drugs, and exercise and/or physical therapy)
Trial: 19228234
Drug: Traditional and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional and non-traditional treatments
Trial: 17708864
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (calcium supplement)
Trial: 15371985
Drug: Trimethoprim 160
RxNorm normalized name: trimethoprim 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 160 mg orally twice daily for 4 days
Trial: 15371985
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg orally once daily for 5 days
Trial: 9439556
Drug: Gliclazide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (80 to 320 mg/d) for 2 years
Trial: 2846022
Drug: Prazosin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (0.5 mg orally)
Trial: 31157575
Drug: Itraconazole pulse
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole pulse therapy (Group I)
Trial: 31157575
Drug: Combined long-pulsed
RxNorm normalized name: Long-acting sulfonamide combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined long-pulsed Nd:Yag laser and itraconazole pulse therapy (Group II)
Trial: 29701045
Drug: Subcutaneous embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous embedding of thumb-tack needle combined with mytear
Trial: 21218643
Drug: Phloroglucinol 80
RxNorm normalized name: phloroglucinol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloroglucinol 80 mg daily for 3 days
Trial: 15390130
Drug: Dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonists (either in monotherapy or in combination)
Trial: 14617226
Drug: Pramlintide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (120 μg bid) + insulin
Trial: 3907825
Drug: Cyclophosphamide at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide at a dose of 1500 mg/m2 every 3 weeks for 1 year
Trial: 27219721
Drug: 7-layer-coating implant
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-layer-coating implant
Trial: 30547305
Drug: Standard TKA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TKA implant
Trial: 22230474
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g mushroom powder
Trial: 22230474
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g mushroom powder
Trial: 22230474
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g mushroom powder (control)
Trial: 2184513
Drug: Ketoconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (400 mg daily)
Trial: 9972860
Drug: Trimethaphan (peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethaphan (peripheral nicotinic receptor antagonist)
Trial: 7726398
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered at 1 mg/kg lean body mass followed by a 4-hour infusion at 5 mg.kg-1.h-1 during hypothermia (34 degrees C)
Trial: 7726398
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered at 1 mg/kg lean body mass followed by a 4-hour infusion at 5 mg.kg-1.h-1 during normothermia (37 degrees C)
Trial: 7726398
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg/kg administered as an intravenous bolus during hypothermia (34 degrees C)
Trial: 1319523
Drug: Midazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (1 mg) administered before injection of LA
Trial: 6719042
Drug: Aspirin (Bayer)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (Bayer) 500 mg
Trial: 6719042
Drug: Reumyl (Hässle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reumyl (Hässle) 500 mg
Trial: 11840418
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (taxane and platinum compound)
Trial: 11840418
Drug: Second-line treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatments (not specified)
Trial: 2306061
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of ranitidine (75, 150, and 300 mg every 24 hours)
Trial: 23837918
Drug: CHOCAF (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOCAF (25 g carbohydrate + 100 mg caffeine)
Trial: 8059918
Drug: 28 days
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28 days of sodium stibogluconate (Pentostam) at 20 mg/kg/day
Trial: 8059918
Drug: 40 days
RxNorm normalized name: Viibryd 10/20/40 30 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 days of sodium stibogluconate (Pentostam) at 20 mg/kg/day
Trial: 3189721
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (after reinstitution of treatment)
Trial: 3189721
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (withdrawal)
Trial: 29710164
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg twice daily) + Aspirin (100 mg once daily)
Trial: 25271201
Drug: Yoga therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga therapy (3-month yoga course of group classes and home practice)
Trial: 21812923
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolic acid (MPA) with standard dose cyclosporine (SD‐CsA)
Trial: 16495245
Drug: Telbivudine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 25 mg/day
Trial: 16495245
Drug: Telbivudine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 400 mg/day
Trial: 16495245
Drug: Telbivudine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 800 mg/day
Trial: 16495245
Drug: Telbivudine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine (all doses)
Trial: 12605972
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment schedules (Conventional and Hypofractionated)
Trial: 11092290
Drug: NPH human
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH human insulin
Trial: 3097726
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg nicotine during stress
Trial: 3097726
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg nicotine alone
Trial: 22775412
Drug: Atorvastatin lactone
RxNorm normalized name: citronellene lactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin lactone
Trial: 23247745
Drug: Atorvastatin acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin acid
Trial: 20104219
Drug: Long-term low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Long-term low-dose peginterferon alpha-2a (90 microg/week)
Trial: 18779512
Drug: CGRP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CGRP infusion (1.5 microg/min)
Trial: 16137507
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (250 ml daily, Cabernet Sauvignon)
Trial: 8485067
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg bid
Trial: 30209126
Drug: Apixaban and
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban and Warfarin
Trial: 23702006
Drug: Transfusion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM) at haemoglobin level (Hb) of 7 g/dl
Trial: 23702006
Drug: Transfusion with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM) at haemoglobin level (Hb) of 9 g/dl
Trial: 15167303
Drug: High-dose (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (80 mg isoflavones + 500 mg calcium)
Trial: 15167303
Drug: Mid-dose (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose (40 mg isoflavones + 500 mg calcium)
Trial: 15844675
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (CBT)
Trial: 11874640
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment with no formal psychosocial intervention (Control)
Trial: 8690170
Drug: Hypoglycaemia (2.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (2.9 mmol/l) for 2 hours during hypo week
Trial: 8690170
Drug: Euglycaemia (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (5 mmol/l) for 2 hours during control week
Trial: 2543203
Drug: Typical Western
RxNorm normalized name: Western Horsetail Top
DrugBank: Equisetum arvense top (DB14349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical Western diet (40% of total calories from fat, 400 mg cholesterol/d, 12 g dietary fiber/d, P:S of 0.5)
Trial: 8299660
Drug: Terbutaline 5
RxNorm normalized name: terbutaline 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 5 mg
Trial: 9598014
Drug: 5% glycolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glycolic acid cream
Trial: 22256334
Drug: 62% ethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62% ethyl alcohol in emollient gel applied by male partners each morning and before and after sexual intercourse
Trial: 16584059
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg FA
Trial: 16584059
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg FA
Trial: 17087779
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg FA
Trial: 24793176
Drug: Monthly intervention
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intervention group (GIM): instructions on fall prevention and healthy exercises with monthly refresher sessions.
Trial: 22537767
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (2 mg/day) + MPA (5mg/day)
Trial: 22537767
Drug: Estradiol-only therapy
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol-only therapy
Trial: 1830636
Drug: All hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All hormone regimens
Trial: 20666584
Drug: tgAAC09 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tgAAC09 (2 doses)
Trial: 10341854
Drug: Interleukin-2 treatment
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-2 treatment
Trial: 21204686
Drug: Brief Direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Direct Treatment Intervention (BDTI)
Trial: 9374124
Drug: 0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/d fish oil (control)
Trial: 1347210
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Breathing Retraining and Cognitive Restructuring with Self-Exposure
Trial: 1347210
Drug: Further treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further treatment during follow-up period
Trial: 1347210
Drug: Demographic variables,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographic variables, pre- and posttest scores, medication use
Trial: 23732372
Drug: Tuberil® (weight-loss
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberil® (weight-loss supplement derived from potato)
Trial: 20163990
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta and high-dose daclizumab (2 mg/kg every 2 weeks)
Trial: 20163990
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta and low-dose daclizumab (1 mg/kg every 4 weeks)
Trial: 11938858
Drug: Salvia miltiorrhiza
RxNorm normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia miltiorrhiza compound injection (SMCI) 200 mg/kg intravenously before operation and at rewarming
Trial: 1302811
Drug: Isoconazole nitrate
RxNorm normalized name: isoconazole nitrate
DrugBank: Isoconazole (DB08943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoconazole nitrate (1% cream, Travogen)
Trial: 1302811
Drug: Clotrimazole (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (1% cream, Canestan)
Trial: 3891821
Drug: Diltiazem (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (high dose 240 mg/day)
Trial: 30741790
Drug: PLLA injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLLA injections
Trial: 7368149
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injections (control group)
Trial: 27904000
Drug: Medium chain
RxNorm normalized name: Medium chain triglyceride
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium chain triglycerides oil (6 g/d for 8 weeks)
Trial: 26976420
Drug: High fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fluid intake along with antimyeloma therapy
Trial: 26976420
Drug: High-cutoff hemodialysis
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-cutoff hemodialysis membranes in combination with antimyeloma therapy
Trial: 26976420
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m(2) to 140 mg/m(2))
Trial: 14533654
Drug: Oral ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ingestion of biogenic amines (specific types not detailed)
Trial: 11739444
Drug: Acipimox (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (500 mg)
Trial: 7851578
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (LA; Lupron) 0.1 mg SC daily for 3 months
Trial: 7851578
Drug: Danazol (Danocrine)
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol (Danocrine) 800 mg orally daily for 3 months
Trial: 6108895
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg tiotidine
Trial: 6108895
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tiotidine
Trial: 31950152
Drug: Novel medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel medications co-administered with alcohol
Trial: 28646807
Drug: Kaltenborn‐Evjenth orthopedic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaltenborn‐Evjenth orthopedic manual therapy (KEOMT) combined with cryotherapy (KEOMT‐C)
Trial: 28646807
Drug: Kaltenborn‐Evjenth orthopedic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaltenborn‐Evjenth orthopedic manual therapy (KEOMT) combined with Kinesio taping (KEOMT‐K)
Trial: 22402257
Drug: EE 20
RxNorm normalized name: AcidFree 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 20 mcg/drsp 3 mg in a 21/7-day regimen
Trial: 19671292
Drug: Multimodal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal group (Group M) with intravenous fentanyl and atracurium, inhalation of nitrous oxide/oxygen (50%:50%) and sevoflurane (5%)
Trial: 19671292
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group C) with inhalation of nitrous oxide/oxygen (50%:50%) and sevoflurane (5%)
Trial: 17722318
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg oral misoprostol
Trial: 7030652
Drug: Flunisolide aerosol
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide aerosol 0.5 mg (two inhalations) twice daily
Trial: 25819701
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy based self-help introduced by CDAT workers